Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Price & Overview
NASDAQ:FDMT • US35104E1001
Current stock price
9.09 USD
+0.22 (+2.48%)
At close:
9.09 USD
0 (0%)
After Hours:
The current stock price of FDMT is 9.09 USD. Today FDMT is up by 2.48%. In the past month the price decreased by -4.11%. In the past year, price increased by 141.76%.
FDMT Key Statistics
52-Week Range3 - 12.34
Current FDMT stock price positioned within its 52-week range.
1-Month Range8.64 - 10.88
Current FDMT stock price positioned within its 1-month range.
- Market Cap
- 464.045M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.42
- Dividend Yield
- N/A
FDMT Stock Performance
Today
+2.48%
1 Week
-3.30%
1 Month
-4.11%
3 Months
+2.60%
Longer-term
6 Months -20.96%
1 Year +141.76%
2 Years -62.08%
3 Years -50.49%
5 Years -65.78%
10 Years N/A
FDMT Stock Chart
FDMT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to FDMT. When comparing the yearly performance of all stocks, FDMT is one of the better performing stocks in the market, outperforming 93.44% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
FDMT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to FDMT. While FDMT has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
FDMT Earnings
On March 18, 2026 FDMT reported an EPS of 0.43 and a revenue of 85.09M. The company beat EPS expectations (155.29% surprise) and beat revenue expectations (808.69% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 18, 2026
PeriodQ4 / 2025
EPS Reported$0.43
Revenue Reported85.09M
EPS Surprise 155.29%
Revenue Surprise 808.69%
FDMT Forecast & Estimates
17 analysts have analysed FDMT and the average price target is 29.35 USD. This implies a price increase of 222.92% is expected in the next year compared to the current price of 9.09.
For the next year, analysts expect an EPS growth of -64.94% and a revenue growth 14.48% for FDMT
Analysts
Analysts82.35
Price Target29.35 (222.88%)
EPS Next Y-64.94%
Revenue Next Year14.48%
FDMT Index Membership
FDMT is currently included in the following stock indexes tracked on ChartMill.
FDMT Financial Highlights
Over the last trailing twelve months FDMT reported a non-GAAP Earnings per Share(EPS) of -2.42. The EPS increased by 18.79% compared to the year before.
Income Statements
Revenue(TTM)85.21M
Net Income(TTM)-140.11M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.72% | ||
| ROE | -27.71% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%147.78%
Sales Q2Q%8508900%
EPS 1Y (TTM)18.79%
Revenue 1Y (TTM)230194.59%
FDMT Ownership
Ownership
Inst Owners105.87%
Shares51.05M
Float49.20M
Ins Owners3.54%
Short Float %23.41%
Short Ratio15.11
FDMT Industry Overview
FDMT operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
FDMT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FDMT
Company Profile
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. The company is headquartered in Emeryville, California and currently employs 227 full-time employees. The company went IPO on 2020-12-11. The firm's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The firm is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The firm's non-core programs include 4D-175, 4D-725, and 4D-310.
Company Info
IPO: 2020-12-11
4D MOLECULAR THERAPEUTICS IN
5858 Horton Street #455, Emeryville
Emeryville CALIFORNIA US
Employees: 196
Phone: 15105052680
4D MOLECULAR THERAPEUTICS IN / FDMT FAQ
What does FDMT do?
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. The company is headquartered in Emeryville, California and currently employs 227 full-time employees. The company went IPO on 2020-12-11. The firm's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The firm is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The firm's non-core programs include 4D-175, 4D-725, and 4D-310.
What is the stock price of 4D MOLECULAR THERAPEUTICS IN today?
The current stock price of FDMT is 9.09 USD. The price increased by 2.48% in the last trading session.
What is the dividend status of 4D MOLECULAR THERAPEUTICS IN?
FDMT does not pay a dividend.
What is the ChartMill rating of 4D MOLECULAR THERAPEUTICS IN stock?
FDMT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is 4D MOLECULAR THERAPEUTICS IN (FDMT) stock traded?
FDMT stock is listed on the Nasdaq exchange.
What is the expected growth for FDMT stock?
The Revenue of 4D MOLECULAR THERAPEUTICS IN (FDMT) is expected to grow by 14.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for 4D MOLECULAR THERAPEUTICS IN?
4D MOLECULAR THERAPEUTICS IN (FDMT) currently has 196 employees.